Background: Influenza B is characterised by two antigenic lineages: B/Victoria and B/ Yamagata. These lineages circulate together with influenza A during influenza seasons, with varying incidence from year to year and by geographic region. 
Influenza B virus circulates in the population alongside influenza A, to varying degrees from season to season and by geographic region. 13, 14 Influenza B was first isolated in the 1940s. The B/Victoria-like virus strain predominated during the 1980s and the B/Yamagata-like virus strain emerged in the late 1990s. 15 These two lineages of influenza B are antigenically and genetically different and studies in ferrets found no cross-reactivity between the two strains. 16 In recent decades, both lineages have cocirculated with varying relative intensity in the same season in many parts of the world including Australia. 17, 18 While influenza B is thought to evolve more slowly than A, the interaction between the two virus types played a key role in the viral evolution process. 6, 17 It has been suggested that influenza type B and the influenza A (H1N1) subtype have slower antigenic evolution and fewer epidemic episodes, resulting in fewer global movements, compared with influenza A/H3N2. A complex network of interacting factors such as viral evolution, epidemiology and human behaviour may describe different patterns of global circulation among influenza viruses. 6, 19 It is not clear whether influenza B infection has similar clinical symptoms to influenza A infection including pandemic strain A/ H1N1pdm09. 20 Studies have shown controversial findings of clinical features in cases infected with A and B infections. [21] [22] [23] In both paediatric and adult populations, patients with influenza B infection showed similar clinical features compared with influenza A. 22, [24] [25] [26] Like influenza A, influenza B infection can lead to severe complications and death, in both children and adults. [27] [28] [29] However, another study found that abdominal pain, vomiting/diarrhoea, headache, general weakness, rhinorrhoea, pharyngitis and otitis were more common with influenza B infection compared with A/H3N2 in adults. 30 Pathological evidence of bacterial pneumonia and myocardial injury was reported from the autopsy tissue samples from cases with fatal influenza B infection in both children and adults. 31 Similar to influenza A, influenza B infection can present with neurological manifestations, such as febrile seizure and encephalitis/encephalopathy in hospitalised children. 28 Inactivated, trivalent influenza vaccine (TIV) was first introduced in the late 1970s and since then it has been widely used for prevention of influenza infection in many countries. protection against unmatched influenza B infections and has comparable safety measures to TIV in both children and adults. [38] [39] [40] The incidence of influenza B infection varies considerably by influenza season and by global region. 14 Here, the aim of our study was to describe the epidemiology and contribution of influenza B relative to influenza A in Australia. 
| METHODS

| Study data and analysis
In the data set received, the recorded date of onset was used for the disease onset date if available. Otherwise, the earliest of the specimen 44 We calculated the agespecific notification rate per 100 000 population for each of influenza A and B for the year, in which influenza B represented at least 20% of notifications in the year. In addition, we examined the proportion of each influenza B lineage across different age groups in the study.
| Mismatch with TIV vaccine B lineage
We also determined the number of years where mismatch occurred between the TIV vaccine B lineage and the circulating B lineage in Australia for the study period. The NNDSS also provided subtype and lineage data as part of the data request in our study, but few notifications included the information. 
| Ethics approval
Ethical approval was received for this study from the University of New South Wales, reference number (HREA-Ref: 2014-7-62). For seasons in which influenza B represented at least 20% of all notifications, age-specific notification rates per 100 000 population are shown in Figure 3A Of influenza B notifications, lineage information was reported for 1216 notifications (2.6% of total B cases) over the entire study period.
| RESULTS
Of these, B/Victoria and B/Yamagata contributed 77.1% and 22.9%,
respectively. There was a trend towards a higher proportion of Victoria lineage in 10-to 19-year-olds. Otherwise, there was limited variation by age (Figure 4 ). In addition, majority of influenza notifications had limited information regarding further subtypes or lineages in the data set. For influenza B, a small proportion of notifications had lineage information available by year, which is presented in the Table S1 . Table 2 shows the comparison between the circulating B lineage and the vaccine B lineage included in the Southern Hemisphere seasonal TIV in Australia for the study period. Influenza B lineage mismatches occurred in just over one-third (5 of 14 seasons) as shown in Table 2 .
Timing of peak influenza activity also varied between influenza A and B in the study. The peak influenza B activity appeared later than influenza A in seven seasons (54%), and the epidemic peak of both in- 14 In that study, the highest median proportion of influenza B was found in tropical regions and the lowest was in the Southern Hemisphere, but when compared between the geographic regions, the differences were not statistically significant. An explanation for the lower proportion in Australia may arise from the higher incidence of influenza B in younger age groups, combined with Australia's older age distribution compared with the aggregated global population. 46 In addition, our study showed a broadly similar proportion of influenza B infection across Australia. As influenza typing to the A and B level was virtually complete in our data, we believe that this result is not geographically biased. Consistent with other studies, 14, 47, 48 influenza B affected children and teenagers more than adults in the study. We found that 2012 had a higher rate of influenza A notifications, with increased notifications particularly in younger children and older adults. This was likely due to higher circulation of A/H3N2 during that season and changes in the viral subtype after the sustained presence of the pandemic 2009 strain for the preceding years. 49 In Australia, 2012 was reported as a severe influenza season, as A/H3N2 tends to be, with increased influenzarelated morbidity and mortality observed. 50, 51 In general, peak influenza B activity arrived later in the season than peak influenza A, and both types cocirculated in each season to varying amounts. However, this relative incidence pattern can vary across different regions of the world, 52 although our finding is comparable to results from France, where influenza B peaked an average of 3.8 weeks later than influenza A. 14,18
| DISCUSSION
In our study, lineage was reported in 2.6% of the total B noti- Many studies have reported the cost-effectiveness and advantages of QIV over the trivalent vaccine. [59] [60] [61] [62] [63] If TIVs were replaced with QIVs in immunisation programmes; this could provide benefit at both the individual and population levels through reduced numbers of infections arising from TIV influenza B and circulating influenza B lineage mismatch. However, adoption of QIV may be constrained in some settings depending on the resources and healthcare system capacity in the country. Thus, switching to QIV should be considered according to available resources, with emphasis on high-risk groups. In addition, there needs to be more research into the effectiveness and costbenefit profile of QIV over TIV.
There are limitations in the study. Our study included data only from notified cases, and thus, laboratory-confirmed influenza notifications may underestimate the true incidence of influenza infections in the population. 12 Only a small proportion of persons infected with influenza will seek medical attention and therefore have the opportunity to be tested. Testing of patients seeking medical care is at the discretion of the medical practitioner, or may vary by local testing conventions, and these practices may vary over time. Besides, there were increased notifications received by NNDSS in the later years during the study; therefore, it is important to interpret these changes over time with caution. We noticed that the total number of influenza notifications were high in 2009, a pandemic year which triggered a much higher demand for testing, and from 2011 onwards. However, the reasons for increased testing/notifications are not fully understood. 64, 65 Moreover, diagnostic practices and test types used by laboratories may change over time, and by laboratory (public and private) and by regional health jurisdiction, especially in relation to subtyping or genotyping of influenza viruses. However, these biases are offset in our study because we focused mainly on differences between influ- 
